martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 12, 2026

Michael Burry is still shorting Palantir — and says Anthropic is the bigger AI winner

View original at finance.yahoo.com
Michael Burry is still shorting Palantir — and says Anthropic is the bigger AI winner Michael Burry, most famous for shorting the housing market ahead of the 2008 financial crisis, said that ‘Anthropic is eating Palantir’s lunch’ in a now-deleted post on X (1)…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OpenAI is the company with the most adopted model overall, with 34.4% of U.S. businesses having a paid subscription

    60% confidence
  • 73.3% of new businesses choose Anthropic over OpenAI when they spend on AI for the first time

    60% confidence
  • Anthropic's product is the easier, cheaper, intuitive solution for businesses

    60% confidence
  • Burry has maintained put options on Palantir since fall 2025 and is not planning on selling them despite Trump's posts

    60% confidence
  • Palantir's government contracts are low margin and small

    60% confidence
  • Anthropic went from $9B to $30B in months, while it took Palantir 20 years to get to $5 billion

    60% confidence
  • Anthropic is taking 73% of all new enterprise spending per Ramp

    60% confidence
  • Anthropic is eating Palantir's lunch

    60% confidence
  • Anthropic is in second place at 24.4% of U.S. businesses with paid subscriptions

    60% confidence

Data points we hold from this source

Anthropic · new customer preference73.3 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com